Abiopharma

🔍 ROMANO KATHRYN (Executive)

Company: Krystal Biotech, Inc. (KRYS)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Common Stock at $63.55 per share (Direct)
  Date: 2026-02-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,818.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,000 shares of Common Stock at $270.5579 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 29,818.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,700 shares of Common Stock at $271.6627 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 24,118.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 2,824 shares of Common Stock at $272.5079 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,294.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 928 shares of Common Stock at $273.7075 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,366.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 552 shares of Common Stock at $274.6388 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,814.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 400 shares of Common Stock at $275.68 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,414.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 96 shares of Common Stock at $277.88 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,318.00 | transaction_form_type: 4 | Footnotes: F8
• Sold 750 shares of Common Stock (Direct)
  Date: 2026-02-09 | Code: G | equity_swap_involved: 0 | shares_owned_after: 18,568.00 | transaction_form_type: 4 | Footnotes: F9
• Sold 12,500 shares of Stock Option (Right to Buy) at $63.55 per share (Derivative)
  Date: 2026-02-09 | Code: M | Expires: 2032-02-27 | equity_swap_involved: 0 | shares_owned_after: 12,500.00 | transaction_form_type: 4 | Footnotes: F1, F10

Footnotes:

• F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
• F2: The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F3: The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F4: The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F5: The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F6: The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F7: The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F8: The transaction was executed in a single trade.
• F9: Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund.
• F10: The options vested ratably over a four-year period beginning on February 28, 2022.